FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alwin Huitema

Research Profile

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Physiology

Drug Interactions

Co-author Network

Publications

TOP 3
Johan G C van Hasselt; Natasha K A van Eijkelenburg; Alwin D R Huitema; Jan H M Schellens; Antoinette Y N Schouten-Van Meeteren
Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate.
Lot A Devriese; Geoff Edwards; Alwin D R Huitema; Kenneth Law; Serena Marchetti; Fuping Peng; Larisa Reyderman; Jos H Beijnen; William Copalu; Emile E Voest; Jantien Wanders; Petronella Els O Witteveen; Jan H M Schellens
Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
Bojana Milojkovic Kerklaan; Jos H Beijnen; Veronique Diéras; Anne-Sophie Govaerts; Alwin D R Huitema; Bojana Milojkovic Kerklaan; Christophe Le Tourneau; Sandrine Marreaud; Marja Mergui-Roelvink; Martine J Piccart-Gebhart; Hilde Rosing; Jan H M Schellens; Ahmad Awada
Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alwin Huitema (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Johan G C van Hasselt; Natasha K A van Eijkelenburg; Alwin D R Huitema; Jan H M Schellens; Antoinette Y N Schouten-Van Meeteren
Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate.
Antimicrobial agents and chemotherapy 2013;57(6):2878-81.
2013: Lot A Devriese; Geoff Edwards; Alwin D R Huitema; Kenneth Law; Serena Marchetti; Fuping Peng; Larisa Reyderman; Jos H Beijnen; William Copalu; Emile E Voest; Jantien Wanders; Petronella Els O Witteveen; Jan H M Schellens
Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
British journal of clinical pharmacology 2013;75(2):507-15.
2013: Bojana Milojkovic Kerklaan; Jos H Beijnen; Veronique Diéras; Anne-Sophie Govaerts; Alwin D R Huitema; Bojana Milojkovic Kerklaan; Christophe Le Tourneau; Sandrine Marreaud; Marja Mergui-Roelvink; Martine J Piccart-Gebhart; Hilde Rosing; Jan H M Schellens; Ahmad Awada
Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.
Cancer chemotherapy and pharmacology 2013;71(1):53-62.
2012: J.G. Coen van Hasselt; Jos H Beijnen; Melvin R Mac Gillavry; Jan H M Schellens; Alwin D R Huitema
Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab.
Pharmaceutical research 2012;29(12):3499-511.
2012: M P H van den Broek; J.G. Coen van Hasselt; H L M van Straaten; Mona C Toet; Linda S de Vries; A C G Egberts; Floris Groenendaal; Alwin D R Huitema; Carin M A Rademaker
Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach.
Clinical pharmacokinetics 2012;51(10):671-9.
2012: Maarten A Wildeman; Jan Paul de Boer; Alwin D R Huitema; Hedy Juwana; Jaap Middeldorp; Zlata Novalic; I Bing Tan; Sandra A W M Verkuijlen; Astrid E Greijer
Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(18):5061-70.
2012: Markus Joerger; Stefanie Kraff; Berta Moritz; Jan H M Schellens; Jos H Beijnen; Gary Feiss; Alwin D R Huitema; Ulrich Jaehde
Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
Clinical pharmacokinetics 2012;51(9):607-17.
2012: Ron J Keizer; Jan H M Schellens; Anthe S Zandvliet; Jos H Beijnen; Alwin D R Huitema
Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses.
The AAPS journal 2012;14(3):601-11.
2012: Thomas P C Dorlo; Manica Balasegaram; Jos H Beijnen; Peter de Vries; María Angeles Lima; Alwin D R Huitema
Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.
The Journal of antimicrobial chemotherapy 2012;67(8):1996-2004.
2012: Ron J Keizer; Jan H M Schellens; Robert Shumaker; Jos H Beijnen; Anubha Gupta; Alwin D R Huitema
Model-based treatment optimization of a novel VEGFR inhibitor.
British journal of clinical pharmacology 2012;74(2):315-26.
2012: Ron J Keizer; Jan H M Schellens; Anthe S Zandvliet; Jos H Beijnen; Alwin D R Huitema
Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).
Investigational new drugs 2012;30(4):1519-30.
2012: Thomas P C Dorlo; Alwin D R Huitema; Jos H Beijnen; Peter de Vries
Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.
Antimicrobial agents and chemotherapy 2012;56(7):3864-72.
2012: Wiete Kromdijk; Jan W Mulder; Hilde Rosing; Patrick M Smit; Jos H Beijnen; Alwin D R Huitema
Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz.
The Journal of antimicrobial chemotherapy 2012;67(5):1211-6.
2012: Markus Joerger; Egbert F Smit; Paul H M Smits; Andrew Vincent; Paul Baas; Martin P L Bard; Jos H Beijnen; Sjaak A Burgers; Valerie D Doodeman; Tjeerd J Haitjema; Alwin D R Huitema; Jan H M Schellens
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
Cancer 2012;118(9):2466-75.
2012: Anne-Charlotte Dubbelman; Alwin D R Huitema; Robert S Jansen; Barbara Koetz; Arturo Lopez-Anaya; Margarita Lymboura; Marja Mergui-Roelvink; Larisa Reyderman; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(2):313-21.
2012: Markus Joerger; Stephan Krähenbühl; Jan H M Schellens; Emanuele Zucca; Thomas Cerny; Andrés J M Ferreri; Alwin D R Huitema
Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.
British journal of clinical pharmacology 2012;73(2):240-7.
2012: J G Coen van Hasselt; Jos H Beijnen; Dieta Brandsma; Jan H M Schellens; Michel M van den Heuvel; Alwin D R Huitema
Severe cannabinoid intoxication in a patient with non-small-cell lung cancer.
Journal of palliative care 2012;28(1):60-1.
2011: Nienke A G Lankheet; Henk Mallo; Hilde Rosing; Jan H M Schellens; Sandra Adriaansz; Christian U Blank; Alwin D R Huitema; Jos H Beijnen
Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.
Journal of analytical toxicology 2011;35(8):558-65.
2011: Elena Soto; Iñaki F Trocóniz; Jantien Wanders; Jos H Beijnen; Josep María Cendrós; Lena E Friberg; Alwin D R Huitema; Ron J Keizer; Rosendo Obach; Concepción Peraire; Jan H M Schellens; Mats O Karlsson
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.
Investigational new drugs 2011;29(5):984-95.
2011: Marcel P H van den Broek; J.G. Coen van Hasselt; Mona C Toet; Linda S de Vries; Toine C G Egberts; Floris Groenendaal; Alwin D R Huitema; Carin M A Rademaker
Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures.
Clinical pharmacokinetics 2011;50(7):461-9.
2011: Rob ter Heine; Robert A B van Waterschoot; Ron J Keizer; Jos H Beijnen; Alfred H Schinkel; Alwin D R Huitema
An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.
Journal of pharmaceutical sciences 2011;100(6):2508-15.
2011: Rob ter Heine; Jan W Mulder; Eric C M van Gorp; Jiri Fp Wagenaar; Jos H Beijnen; Alwin D R Huitema
Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.
Bioanalysis 2011;3(10):1093-7.
2011: Nienke A G Lankheet; Roos D Padberg; Evelyne M de Kluiver; Abraham J Wilhelm; Job B M van Woensel; Jos H Beijnen; Alwin D R Huitema
Relatively mild symptoms after an olanzapine intoxication in a 2-year-old girl with excessively high serum levels.
Journal of child and adolescent psychopharmacology 2011;21(1):93-5.
2011: Ron J Keizer; J H M Schellens; Jos H Beijnen; Alwin D R Huitema
Pharmacodynamic biomarkers in model-based drug development in oncology.
Current clinical pharmacology 2011;6(1):30-40.
2011: L Tran; Joke W Baars; Jan Paul de Boer; Cornelis A Hoefnagel; Jos H Beijnen; Alwin D R Huitema
The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.
Human antibodies 2011;20(1-2):37-40.
2011: L Tran; Alwin D R Huitema; M H van Rijswijk; H J Dinant; Joke W Baars; Jos H Beijnen; Wouter V Vogel
CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.
Human antibodies 2011;20(1-2):29-35.
2011: L Tran; Wouter V Vogel; M Sinaasappel; S Muller; Joke W Baars; M van Rijswijk; H J Dinant; Jos H Beijnen; Alwin D R Huitema
The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis.
Human antibodies 2011;20(1-2):7-14.
2011: Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.
Computer methods and programs in biomedicine 2011;101(1):72-9.
2010: Ron J Keizer; Anubha Gupta; Melvin R Mac Gillavry; Mendel Jansen; Jantien Wanders; Jos H Beijnen; Jan H M Schellens; Mats O Karlsson; Alwin D R Huitema
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.
Journal of pharmacokinetics and pharmacodynamics 2010;37(4):347-63.
2010: Ron J Keizer; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Clinical pharmacokinetics of therapeutic monoclonal antibodies.
Clinical pharmacokinetics 2010;49(8):493-507.
2010: Rob ter Heine; Hilde Rosing; Jos H Beijnen; Alwin D R Huitema
A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2010;48(8):1153-5.
2010: Robert A B van Waterschoot; Rob ter Heine; Els Wagenaar; C M M van der Kruijssen; R W Rooswinkel; Alwin D R Huitema; Jos H Beijnen; Alfred H Schinkel
Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
British journal of pharmacology 2010;160(5):1224-33.
2010: Rob ter Heine; Jan W Mulder; Eric C M van Gorp; Jiri F P Wagenaar; Jos H Beijnen; Alwin D R Huitema
Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
British journal of clinical pharmacology 2010;69(5):475-83.
2010: Stijn L W Koolen; Roos L Oostendorp; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.
British journal of clinical pharmacology 2010;69(5):465-74.
2010: Wiete Kromdijk; Alwin D R Huitema; Jan Willem Mulder
Treatment of HIV infection with the CCR5 antagonist maraviroc.
Expert opinion on pharmacotherapy 2010;11(7):1215-23.
2010: Anthe S Zandvliet; Mats O Karlsson; Jan H M Schellens; William Copalu; Jos H Beijnen; Alwin D R Huitema
Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents.
Investigational new drugs 2010;28(1):61-75.
2010: Andrew K L Goey; J H M Schellens; Jos H Beijnen; Alwin D R Huitema
[Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Nederlands tijdschrift voor geneeskunde 2010;154():A1155.
2010: L Tran; J W Baars; L Aarden; Jos H Beijnen; Alwin D R Huitema
Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.
Human antibodies 2010;19(1):7-13.
2009: Stijn L W Koolen; Alwin D R Huitema; Robert S Jansen; Theo van Voorthuizen; Jos H Beijnen; Willem M Smit; Jan H M Schellens
Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature.
The oncologist 2009;14(9):944-8.
2009: R ter Heine; M J X Hillebrand; H Rosing; Eric C M van Gorp; Jan W Mulder; Jos H Beijnen; Alwin D R Huitema
Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(9):1826-40.
2009: Roos L Oostendorp; Alwin D R Huitema; Hilde Rosing; Robert Jansen; Rob ter Heine; Marianne Keessen; Jos H Beijnen; Jan H M Schellens
Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4228-33.
2009: Corine Ekhart; Sjoerd Rodenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Cancer chemotherapy and pharmacology 2009;64(1):115-22.
2009: Ron J Keizer; Miren K Zamacona; Mendel Jansen; David Critchley; Jantien Wanders; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820.
Investigational new drugs 2009;27(2):140-52.
2009: R Ter Heine; M J X Hillebrand; H Rosing; E C M van Gorp; J W Mulder; J H Beijnen; Alwin D R Huitema
Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry.
Journal of pharmaceutical and biomedical analysis 2009;49(2):451-8.
2009: R Ter Heine; Hilde Rosing; Eric C M van Gorp; Jan W Mulder; Jos H Beijnen; Alwin D R Huitema
Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate by liquid chromatography tandem mass spectrometry.
Journal of pharmaceutical and biomedical analysis 2009;49(2):393-400.
2009: R ter Heine; M Davids; Hilde Rosing; Eric C M van Gorp; Jan W Mulder; Y T van der Heide; Jos H Beijnen; Alwin D R Huitema
Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(5-6):575-80.
2009: Ly Tran; Joke W Baars; Harry J Maessen; Cornelis A Hoefnagel; Jos H Beijnen; Alwin D R Huitema
A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy.
Cancer biotherapy & radiopharmaceuticals 2009;24(1):103-10.
2009: Anthe S Zandvliet; Jan H M Schellens; William Copalu; Jos H Beijnen; Alwin D R Huitema
Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.
Journal of pharmacokinetics and pharmacodynamics 2009;36(1):39-62.
2009: Corine Ekhart; Sjoerd Rodenhuis; Jos H Beijnen; Alwin D R Huitema
Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
Therapeutic drug monitoring 2009;31(1):95-103.
2009: Corine Ekhart; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment.
Cancer treatment reviews 2009;35(1):18-31.
2009: Ly Tran; Jos H Beijnen; Alwin D R Huitema
The preparation of radiolabeled monoclonal antibodies for human use.
Human antibodies 2009;18(4):145-56.
2009: Rob ter Heine; Alwin D R Huitema; Robert S Jansen; Paul Hm Smits; Eric C M van Gorp; Jiri Fp Wagenaar; Jos H Beijnen; Jan W Mulder
Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure.
Antiviral therapy 2009;14(2):299-301.
2009: E E M Brouwers; Alwin D R Huitema; Willem Boogerd; Jos H Beijnen; Jan H M Schellens
Persistent neuropathy after treatment with cisplatin and oxaliplatin.
Acta oncologica (Stockholm, Sweden) 2009;48(6):832-41.
2009: Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
British journal of clinical pharmacology 2009;67(1):50-60.
2009: E E M Brouwers; M Söhne; S Kuipers; Eric C M van Gorp; J H M Schellens; Cornelis H W Koks; Jos H Beijnen; Alwin D R Huitema
Ciprofloxacin strongly inhibits clozapine metabolism: two case reports.
Clinical drug investigation 2009;29(1):59-63.
2009: Corine Ekhart; J Martijn Kerst; Sjoerd Rodenhuis; Jos H Beijnen; Alwin D R Huitema
Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
Cancer chemotherapy and pharmacology 2009;63(2):375-9.
2008: Corine Ekhart; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Pharmacogenetics and genomics 2008;18(11):1009-15.
2008: Anthe S Zandvliet; Jan H M Schellens; Christian Dittrich; Jantien Wanders; Jos H Beijnen; Alwin D R Huitema
Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.
British journal of clinical pharmacology 2008;66(4):485-97.
2008: Thomas Dorlo; Pieter P A M van Thiel; Alwin D R Huitema; Ron J Keizer; Henry J C de Vries; Jos H Beijnen; Peter de Vries
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.
Antimicrobial agents and chemotherapy 2008;52(8):2855-60.
2008: E E M Brouwers; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry.
Anti-cancer drugs 2008;19(6):621-30.
2008: Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Pharmacogenetics and genomics 2008;18(6):515-23.
2008: Anthe S Zandvliet; Wandena S Siegel-Lakhai; Jos H Beijnen; William Copalu; M-C Etienne-Grimaldi; G Milano; J H M Schellens; Alwin D R Huitema
PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.
Clinical pharmacology and therapeutics 2008;83(6):829-39.
2008: Rob ter Heine; Hilde Rosing; Eric C M van Gorp; Jan W Mulder; W A van der Steeg; Jos H Beijnen; Alwin D R Huitema
Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;867(2):205-12.
2008: J N H Timmer-Bonte; Cornelis J A Punt; H F M vd Heijden; CE van Die; Johan Bussink; J H Beijnen; Alwin D R Huitema; Vivianne C G Tjan-Heijnen
Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2008;60(2):222-30.
2008: Wandena S Siegel-Lakhai; Anthe S Zandvliet; Alwin D R Huitema; Matthijs M Tibben; G Milano; V Girre; V Diéras; A King; E Richmond; Jantien Wanders; Jos H Beijnen; J H M Schellens
A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.
British journal of cancer 2008;98(8):1320-6.
2008: Rob ter Heine; Henriette J Scherpbier; Kristel M L Crommentuyn; Vincent Bekker; Jos H Beijnen; Taco W Kuijpers; Alwin D R Huitema
A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations.
Antiviral therapy 2008;13(6):779-87.
2008: E E M Brouwers; Alwin D R Huitema; Jos H Beijnen; Jan H M Schellens
Long-term platinum retention after treatment with cisplatin and oxaliplatin.
BMC clinical pharmacology 2008;8():7.
2008: Anthe S Zandvliet; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.
Clinical pharmacokinetics 2008;47(8):487-513.
2007: Markus Joerger; Alwin D R Huitema; Dick J Richel; Christian Dittrich; Nicholas Pavlidis; Evangelos Briasoulis; Jan B Vermorken; Elena Strocchi; Andrea Martoni; Roberto Sorio; Henk P Sleeboom; Miguel A Izquierdo; Duncan I Jodrell; Hilary Calvert; Alan V Boddy; Harry Hollema; Regine Féty; Wjf J F Van der Vijgh; Georg Hempel; Etienne Chatelut; Mats Karlsson; Justin Wilkins; Brigitte Tranchand; Ad H G J Schrijvers; Chris Twelves; Jos H Beijnen; Jan H M Schellens
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6410-8.
2007: Markus Joerger; Alwin D R Huitema; manon huizing; P H B Willemse; A de Graeff; Hilde Rosing; J H M Schellens; Jos H Beijnen; Jan B Vermorken
Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.
British journal of clinical pharmacology 2007;64(5):622-33.
2007: Stephan A Veltkamp; Hilde Rosing; Alwin D R Huitema; M R Fetell; A Nol; Jos H Beijnen; J H M Schellens
Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours.
Cancer chemotherapy and pharmacology 2007;60(5):635-42.
2007: E E M Brouwers; Alwin D R Huitema; E N Bakker; J W Douma; K J M Schimmel; G van Weringh; P J de Wolf; J H M Schellens; Jos H Beijnen
Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry.
International archives of occupational and environmental health 2007;80(8):689-99.
2007: Corine Ekhart; Abadi Gebretensae; Hilde Rosing; Sjoerd Rodenhuis; Jos H Beijnen; Alwin D R Huitema
Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS).
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;854(1-2):345-9.
2007: Anthe S Zandvliet; Alwin D R Huitema; William Copalu; Yasuhide Yamada; Tomohide Tamura; Jos H Beijnen; Jan H M Schellens
CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(10):2970-6.
2007: R J Keizer; Alwin D R Huitema; C W N Damen; J H M Schellens; J H Beijnen
[The pharmacokinetics of monoclonal antibodies].
Nederlands tijdschrift voor geneeskunde 2007;151(12):683-8.
2007: Denis C Talbot; Joachim von Pawel; Emma Cattell; S Murray Yule; Claire Johnston; Anthe S Zandvliet; Alwin D R Huitema; Chris J Norbury; Paul Ellis; Leon Bosquee; Martin Reck
A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1816-22.
2007: Sabien C van der Schoot; Bastiaan Nuijen; Alwin D R Huitema; Jos H Beijnen
Assessment of performance of manufacturing procedures in a unit for production of investigational anticancer agents, using a mixed effects analysis.
Pharmaceutical research 2007;24(3):605-12.
2007: Christian Dittrich; Anthe S Zandvliet; Margit Gneist; Alwin D R Huitema; A A J King; Jantien Wanders
A phase I and pharmacokinetic study of indisulam in combination with carboplatin.
British journal of cancer 2007;96(4):559-66.
2007: Markus Joerger; Alwin D R Huitema; Dick J Richel; Christian Dittrich; Nikolas Pavlidis; Evangelos Briasoulis; Jan B Vermorken; Elena Strocchi; Andrea Martoni; Roberto Sorio; Henk P Sleeboom; Miguel A Izquierdo; Duncan I Jodrell; Régine Féty; Ernst de Bruijn; Georg Hempel; Mats Karlsson; Brigitte Tranchand; Ad H G J Schrijvers; Chris Twelves; Jos H Beijnen; Jan H M Schellens
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
Clinical pharmacokinetics 2007;46(12):1051-68.
2007: Rob ter Heine; Carolien G Alderden-Los; Hilde Rosing; Michel J X Hillebrand; Eric C M van Gorp; Alwin D R Huitema; Jos H Beijnen
Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2007;21(15):2505-14.
2007: Sanjay U C Sankatsing; Marion Cornelissen; Nico Kloosterboer; Kristel M L Crommentuyn; Tessa M Bosch; Frederik P Mul; Suzanne Jurriaans; Alwin D R Huitema; Jos H Beijnen; Joep M A Lange; Jan M Prins; Hanneke Schuitemaker
Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells.
AIDS research and human retroviruses 2007;23(1):19-27.
2006: Corine Ekhart; Milly E De Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Flat dosing of carboplatin is justified in adult patients with normal renal function.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6502-8.
2006: H H Helgason; C M F Kruijtzer; Alwin D R Huitema; S G Marcus; Wim W ten Bokkel Huinink; Margaret Schot; Jan H Schornagel; Jos H Beijnen; J H M Schellens
Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.
British journal of cancer 2006;95(7):794-800.
2006: Tessa M Bosch; Alwin D R Huitema; Valerie D Doodeman; Robert Jansen; Els O Witteveen; Wim M Smit; Rob L Jansen; C M L van Herpen; Marcel Soesan; Jos H Beijnen; Jan H M Schellens
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5786-93.
2006: Anthe S Zandvliet; Jan H M Schellens; William Copalu; Jos H Beijnen; Alwin D R Huitema
A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam.
Journal of pharmacokinetics and pharmacodynamics 2006;33(5):543-70.
2006: E J Vos; Alwin D R Huitema
[Defining trials of medicinal products according to the revised Dutch Medical Research in Human Subjects Act (WMO)].
Nederlands tijdschrift voor geneeskunde 2006;150(38):2104-7.
2006: Stephan A Veltkamp; Bas Thijssen; J S Garrigue; G Lambert; F Lallemand; F Binlich; Alwin D R Huitema; Bastiaan Nuijen; A Nol; Jos H Beijnen; J H M Schellens
A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.
British journal of cancer 2006;95(6):729-34.
2006: Markus Joerger; Alwin D R Huitema; Willem Boogerd; JJ van der Sande; J H M Schellens; Jos H Beijnen
Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
Basic & clinical pharmacology & toxicology 2006;99(2):133-40.
2006: Rolf W Sparidans; Frits Dost; Kristel M L Crommentuyn; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma.
Biomedical chromatography : BMC 2006;20(8):671-3.
2006: Elisabeth J Rook; Alwin D R Huitema; Wim Van den Brink; Michel J X Hillebrand; Jan M Van Ree; Jos H Beijnen
Screening for illicit heroin use in patients in a heroin-assisted treatment program.
Journal of analytical toxicology 2006;30(6):390-4.
2006: Markus Joerger; Alwin D R Huitema; H J G Desirée van den Bongard; P Baas; Jan H Schornagel; J H M Schellens; Jos H Beijnen
Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
British journal of clinical pharmacology 2006;62(1):71-80.
2006: I van den Broek; Rolf W Sparidans; Alwin D R Huitema; J H M Schellens; Jos H Beijnen
Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;837(1-2):49-58.
2006: Kristel M L Crommentuyn; Henriëtte J Scherpbier; Taco W Kuijpers; Ron A A Mathôt; Alwin D R Huitema; Jos H Beijnen
Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
The Pediatric infectious disease journal 2006;25(6):538-43.
2006: Anthe S Zandvliet; William Copalu; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(6):1041-6.
2006: Milly E De Jonge; Alwin D R Huitema; Jos H Beijnen; Sjoerd Rodenhuis
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.
British journal of cancer 2006;94(9):1226-30.
2006: Markus Joerger; Alwin D R Huitema; Desiree H J G van den Bongard; Jan H M Schellens; Jos H Beijnen
Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2150-7.
2006: F Van Leth; Bregt S Kappelhoff; D Johnson; Marcelo H Losso; Anna Boron-Kaczmarska; M S Saag; J-M Livrozet; David B Hall; J Leith; Alwin D R Huitema; Ferdinand W N M Wit; Jos H Beijnen; Joep M A Lange
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
AIDS research and human retroviruses 2006;22(3):232-9.
2006: Elisabeth J Rook; Alwin D R Huitema; Wim van den Brink; Jan M van Ree; Jos H Beijnen
Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature.
Current clinical pharmacology 2006;1(1):109-18.
2006: Elisabeth J Rook; Alwin D R Huitema; Wim Van den Brink; Jan M Van Ree; Jos H Beijnen
Population pharmacokinetics of heroin and its major metabolites.
Clinical pharmacokinetics 2006;45(4):401-17.
2006: Elisabeth J Rook; Jan M Van Ree; Wim Van den Brink; Michel J X Hillebrand; Alwin D R Huitema; Vincent M Hendriks; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients.
Basic & clinical pharmacology & toxicology 2006;98(1):86-96.
2006: Rolf W Sparidans; Frits Dost; Kristel M L Crommentuyn; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Liquid chromatographic assay for the protease inhibitor atazanavir in plasma.
Biomedical chromatography : BMC 2006;20(1):72-6.
2005: Milly E De Jonge; Alwin D R Huitema; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
Therapeutic drug monitoring 2005;27(6):756-65.
2005: Catharina M van Rij; Alwin D R Huitema; Eleonora L Swart; Henri N J M Greuter; Adriaan A Lammertsma; Andre C D van Loenen; Eric J F Franssen
Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations.
British journal of clinical pharmacology 2005;60(5):477-85.
2005: Kristel M L Crommentuyn; Bregt S Kappelhoff; Jan W Mulder; Albert T A Mairuhu; Eric C M van Gorp; Pieter L Meenhorst; Alwin D R Huitema; Jos H Beijnen
Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
British journal of clinical pharmacology 2005;60(4):378-89.
2005: Milly E De Jonge; Alwin D R Huitema; Marjo J Holtkamp; Selma M Van Dam; Jos H Beijnen; Sjoerd Rodenhuis
Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
Cancer chemotherapy and pharmacology 2005;56(4):370-8.
2005: Bregt S Kappelhoff; Alwin D R Huitema; Frank van Leth; Patrick A Robinson; Thomas R MacGregor; Joep M A Lange; Jos H Beijnen
Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
HIV clinical trials 2005;6(5):254-61.
2005: Bregt S Kappelhoff; Alwin D R Huitema; Sanjay U C Sankatsing; Pieter L Meenhorst; Eric C M van Gorp; Jan W Mulder; Jan M Prins; Jos H Beijnen
Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
British journal of clinical pharmacology 2005;60(3):276-86.
2005: Bregt S Kappelhoff; Alwin D R Huitema; Albert T A Mairuhu; Jan H M Schellens; Jos H Beijnen
No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel.
Anti-cancer drugs 2005;16(6):627-30.
2005: Kristel M L Crommentuyn; Alwin D R Huitema; Jos H Beijnen
Bioanalysis of HIV protease inhibitors in samples from sanctuary sites.
Journal of pharmaceutical and biomedical analysis 2005;38(1):139-47.
2005: Milly E De Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).
Therapeutic drug monitoring 2005;27(3):393-402.
2005: Charlotte van Kesteren; Anthe S Zandvliet; Mats O Karlsson; Ron A A Mathôt; Cornelis J A Punt; Jean-Pierre Armand; Eric Raymond; Alwin D R Huitema; Christian Dittrich; Herlinde Dumez; Henri Roché; Jean Pierre Droz; Miroslav Ravic; S Murray Yule; Jantien Wanders; Jos H Beijnen; Pierre Fumoleau; Jan H M Schellens
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
Investigational new drugs 2005;23(3):225-34.
2005: Marjolein G Klous; Alwin D R Huitema; Elisabeth J Rook; Michel J X Hillebrand; Vincent M Hendriks; Wim Van den Brink; Jos H Beijnen; Jan M Van Ree
Pharmacokinetic comparison of two methods of heroin smoking: 'chasing the dragon' versus the use of a heating device.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2005;15(3):263-9.
2005: Markus Joerger; Alwin D R Huitema; Pieter L Meenhorst; J H M Schellens; Jos H Beijnen
Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Cancer chemotherapy and pharmacology 2005;55(5):488-96.
2005: Milly E De Jonge; Alwin D R Huitema; Selma M Van Dam; Jos H Beijnen; Sjoerd Rodenhuis
Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin.
Cancer chemotherapy and pharmacology 2005;55(5):507-10.
2005: Milly E De Jonge; Alwin D R Huitema; Jan Hm Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
British journal of clinical pharmacology 2005;59(3):325-34.
2005: Milly E De Jonge; Alwin D R Huitema; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes.
Anti-cancer drugs 2005;16(3):331-6.
2005: Bregt S Kappelhoff; Alwin D R Huitema; Kristel M L Crommentuyn; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Albert T A Mairuhu; Jos H Beijnen
Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
British journal of clinical pharmacology 2005;59(2):174-82.
2005: Milly E De Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Clinical pharmacokinetics of cyclophosphamide.
Clinical pharmacokinetics 2005;44(11):1135-64.
2005: Bregt S Kappelhoff; Frank van Leth; Patrick A Robinson; Thomas R MacGregor; Ezio Baraldi; Francesco Montella; David E Uip; Melanie A Thompson; Darren B Russell; Joep M A Lange; Jos H Beijnen; Alwin D R Huitema
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Antiviral therapy 2005;10(4):489-98.
2005: Bregt S Kappelhoff; Alwin D R Huitema; Zeynep Yalvaç; Jan M Prins; Jan W Mulder; Pieter L Meenhorst; Jos H Beijnen
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
Clinical pharmacokinetics 2005;44(8):849-61.
2005: Bregt S Kappelhoff; Alwin D R Huitema; Jos H Beijnen
Should non-nucleoside reverse transcriptase inhibitors be combined?
Drugs in R&D 2005;6(2):61-9.
2005: Bregt S Kappelhoff; Frank van Leth; Thomas R MacGregor; Joep Lange; Jos H Beijnen; Alwin D R Huitema
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
Antiviral therapy 2005;10(1):145-55.
2005: Milly E De Jonge; Alwin D R Huitema; Annemarie C Tukker; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):273-83.
2005: Anthe S Zandvliet; Alwin D R Huitema; Milly E De Jonge; Rob den Hoed; Rolf W Sparidans; Vincent M Hendriks; Wim Van den Brink; Jan M Van Ree; Jos H Beijnen
Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine.
Basic & clinical pharmacology & toxicology 2005;96(1):71-9.
2005: Milly E De Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.
Clinical pharmacokinetics 2005;44(2):147-73.
2004: Kristel M L Crommentuyn; Jan W Mulder; Albert T A Mairuhu; Eric C M van Gorp; Pieter L Meenhorst; Alwin D R Huitema; Jos H Beijnen
The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
Antiviral therapy 2004;9(5):779-85.
2004: Monique M R de Maat; Jeannine F J B Nellen; Alwin D R Huitema; Ferdinand W N M Wit; Jan W Mulder; Jan M Prins; Jos H Beijnen
Race is not associated with nevirapine pharmacokinetics.
Therapeutic drug monitoring 2004;26(4):456-8.
2004: Kristel M L Crommentuyn; Hilde Rosing; Michel J X Hillebrand; Alwin D R Huitema; Jos H Beijnen
Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;804(2):359-67.
2004: Kristel M L Crommentuyn; Jan W Mulder; Rolf W Sparidans; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;38(8):e73-5.
2004: Milly E De Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.
Journal of pharmacokinetics and pharmacodynamics 2004;31(2):135-56.
2004: Milly E De Jonge; H J G Desirée van den Bongard; Alwin D R Huitema; Ron A A Mathôt; Hilde Rosing; Paul Baas; nico van zandwijk; Jos H Beijnen; Jan H M Schellens
Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(7):2237-44.
2004: M M R de Maat; Anthonius de Boer; Cornelis H W Koks; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Albert T A Mairuhu; Alwin D R Huitema; J H Beijnen
Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care.
Journal of clinical pharmacy and therapeutics 2004;29(2):121-30.
2004: Milly E De Jonge; Selma M Van Dam; Michel J X Hillebrand; Hilde Rosing; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 2004;39(3):262-71.
2004: Bregt S Kappelhoff; Kristel M L Crommentuyn; Monique M R de Maat; Jan W Mulder; Alwin D R Huitema; Jos H Beijnen
Practical guidelines to interpret plasma concentrations of antiretroviral drugs.
Clinical pharmacokinetics 2004;43(13):845-53.
2004: Sanjay U C Sankatsing; Patrick G Hoggard; Alwin D R Huitema; Rolf W Sparidans; Stephen Kewn; Kristel M L Crommentuyn; Joep M A Lange; Jos H Beijnen; David J Back; Jan M Prins
Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools.
Clinical pharmacokinetics 2004;43(12):823-32.
2003: Alwin D R Huitema; Rob A J Kuiper; Pieter L Meenhorst; Jan W Mulder; Jos H Beijnen
Photophobia in a patient with high indinavir plasma concentrations.
Therapeutic drug monitoring 2003;25(6):735-7.
2003: Monique M R de Maat; Rob ter Heine; Jan W Mulder; Pieter L Meenhorst; Albert T A Mairuhu; Eric C M van Gorp; Alwin D R Huitema; Jos H Beijnen
Incidence and risk factors for nevirapine-associated rash.
European journal of clinical pharmacology 2003;59(5-6):457-62.
2003: Bregt S Kappelhoff; Hilde Rosing; Alwin D R Huitema; Jos H Beijnen
Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;792(2):353-62.
2003: Monique M R de Maat; Alwin D R Huitema; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Albert T A Mairuhu; Jos H Beijnen
Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care.
Therapeutic drug monitoring 2003;25(3):367-73.
2003: Cornelis H W Koks; Alwin D R Huitema; Eugene D M B Kroon; Theshinee Chuenyam; Rolf W Sparidans; Joep M A Lange; Jos H Beijnen
Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons.
Therapeutic drug monitoring 2003;25(2):229-33.
2003: Kristel M L Crommentuyn; Hilde Rosing; Lianda G A H Nan-Offeringa; Michel J X Hillebrand; Alwin D R Huitema; Jos H Beijnen
Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 2003;38(2):157-66.
2003: Monique M R de Maat; Alwin D R Huitema; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Albert T A Mairuhu; Jos H Beijnen
Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals.
Clinical drug investigation 2003;23(10):629-37.
2003: Theodora E M S de Vries-Sluijs; Jeanne P Dieleman; Dennis Arts; Alwin D R Huitema; Jos H Beijnen; Martin Schutten; Marchina E Van Der Ende
Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population.
Clinical pharmacokinetics 2003;42(6):599-605.
2003: Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen
Drug interactions between antiretroviral drugs and comedicated agents.
Clinical pharmacokinetics 2003;42(3):223-82.
2002: Milly E De Jonge; Ron A A Mathôt; Otilia Dalesio; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.
Bone marrow transplantation 2002;30(9):593-7.
2002: Monique M R de Maat; Alwin D R Huitema; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Jos H Beijnen
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
British journal of clinical pharmacology 2002;54(4):378-85.
2002: Alwin D R Huitema; M Spaander; R A A Mathĵt; Matthijs M Tibben; Marjo J Holtkamp; Jos H Beijnen; Sjoerd Rodenhuis
Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(3):374-84.
2001: Alwin D R Huitema; Ron A A Mathôt; Matthijs M Tibben; Sjoerd Rodenhuis; Jos H Beijnen
Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen.
Therapeutic drug monitoring 2001;23(6):650-7.
2001: Thomas Kerbusch; Rob L Jansen; Ron A A Mathôt; Alwin D R Huitema; M Jansen; R E van Rijswijk; Jos H Beijnen
Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
Clinical pharmacology and therapeutics 2001;70(2):132-41.
2001: Thomas Kerbusch; J W vanPutten; Harry J M Groen; Alwin D R Huitema; R A Mathĵt; Jos H Beijnen
Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients.
Cancer chemotherapy and pharmacology 2001;48(1):53-61.
2001: MJ van Maanen; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin.
Anti-cancer drugs 2001;12(6):519-24.
2001: Alwin D R Huitema; C Reinders; Matthijs M Tibben; Sjoerd Rodenhuis; Jos H Beijnen
Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma.
Journal of chromatography. B, Biomedical sciences and applications 2001;757(2):349-57.
2001: Alwin D R Huitema; Ron A A Mathôt; Matthijs M Tibben; Sjoerd Rodenhuis; Jos H Beijnen
A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.
Journal of pharmacokinetics and pharmacodynamics 2001;28(3):211-30.
2001: Alwin D R Huitema; Ron A A Mathôt; Matthijs M Tibben; J H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.
British journal of clinical pharmacology 2001;51(1):61-70.
2000: Thomas Kerbusch; M J Jeuken; J Derraz; J W van Putten; Alwin D R Huitema; Jos H Beijnen
Determination of ifosfamide, 2- and 3-dechloroethyifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detection.
Therapeutic drug monitoring 2000;22(5):613-20.
2000: Alwin D R Huitema; Matthijs M Tibben; Thomas Kerbusch; J Jantina Kettenes-van den Bosch; Sjoerd Rodenhuis; Jos H Beijnen
Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2000;745(2):345-55.
2000: Alwin D R Huitema; K D Smits; Ron A A Mathôt; J H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
The clinical pharmacology of alkylating agents in high-dose chemotherapy.
Anti-cancer drugs 2000;11(7):515-33.
2000: Alwin D R Huitema; Ron A A Mathôt; Matthijs M Tibben; J H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
Clinical pharmacology and therapeutics 2000;67(6):621-30.
2000: Thomas Kerbusch; Alwin D R Huitema; J Ouwerkerk; HJ Keizer; Ron A A Mathôt; J H M Schellens; Jos H Beijnen
Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.
British journal of clinical pharmacology 2000;49(6):555-61.
2000: MJ van Maanen; Alwin D R Huitema; J H Beijen
Influence of co-medicated drugs on the biotransformation of thioTEPA to TEPA and thioTEPA-mercapturate.
Anticancer research 2000;20(3A):1711-6.
2000: Sjoerd Rodenhuis; Alwin D R Huitema; Frits S A M van Dam; Elisabeth G E de Vries; Jos H Beijnen
High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer.
Cancer journal (Sudbury, Mass.) 2000;6 Suppl 2():S125-30.
2000: Alwin D R Huitema; Thomas Kerbusch; Matthijs M Tibben; Sjoerd Rodenhuis; Jos H Beijnen
Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.
Cancer chemotherapy and pharmacology 2000;46(2):119-27.
1999: Alwin D R Huitema; M M J Holtkamp; Matthijs M Tibben; Sjoerd Rodenhuis; Jos H Beijnen
Sampling technique from central venous catheters proves critical for pharmacokinetic studies.
Therapeutic drug monitoring 1999;21(1):102-4.
1998: RJ van Maanen; Ronald D van Ooijen; JW Zwikker; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Determination of N,N',N"-triethylenethiophosphoramide and its active metabolite N,N',N"-triethylenephosphoramide in plasma and urine using capillary gas chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1998;719(1-2):103-12.
1998: Thomas Kerbusch; Alwin D R Huitema; J Jantina Kettenes-van den Bosch; HJ Keizer; J Ouwerkerk; J de Kraker; Jos H Beijnen
High-performance liquid chromatographic determination of stabilized 4-hydroxyifosfamide in human plasma and erythrocytes.
Journal of chromatography. B, Biomedical sciences and applications 1998;716(1-2):275-84.
1998: Alwin D R Huitema; Matthijs M Tibben; Thomas Kerbusch; JW Zwikker; Sjoerd Rodenhuis; Jos H Beijnen
Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1998;716(1-2):177-86.
1998: Alwin D R Huitema; Marcel Soesan; Pieter L Meenhorst; Cornelis H W Koks; Jos H Beijnen
A dose-dependent delayed hypersensitivity reaction to acetaminophen after repeated acetaminophen intoxications.
Human & experimental toxicology 1998;17(7):406-8.